Fibroblast growth factor 23: are we ready to use it in clinical practice?
نویسندگان
چکیده
منابع مشابه
Pharmacogenetics in psychiatry: are we ready for widespread clinical use?
There are high expectations about the capabilities of pharmacogenetics to tailor psychotropic treatment and "personalize" treatment. While a large number of associations, with generally small effect size, have been discovered, a "test" with widespread use and adoption is still missing. A more realistic picture, recognizing the important contribution of clinical and environmental factors toward ...
متن کاملNewborn Screening: Are We Ready for It?
The newborn screening (NBS) programme is a complex and organised system consisting of family and personal education, biochemical tests, confi rmatory biochemical and genetic tests, diagnosis, therapy, and patient follow-up. The programme identifi es treatable metabolic disorders, possibly when still asymptomatic, by using dried blood spot (DBS). Over the last 20 years, tandem mass spectrometry ...
متن کاملDiphtheria: are we ready for it?
Pharyngeal or cutaneous diphtheria is caused by toxigenic strains of Corynebacterium diphtheriae and occasionally by Corynebacterium ulcerans. Both organisms are capable ofproducing an exotoxin that causes local tissue necrosis, and when absorbed into the bloodstream causes toxaemia and systemic complications that include demyelinating peripheral neuritis with associated paralysis and myocardit...
متن کاملDelta cardiac troponin values in practice: are we ready to move absolutely forward to clinical routine?
The improved analytical characteristics of both sensitive and high-sensitivity assays for cardiac troponins I (cTnI) and T (cTnT) have substantially increased the diagnostic sensitivity for early detection of acute myocardial infarction (AMI) (1–3 ). With the ability to detect small increases in circulating cardiac troponins, any cause of myocardial injury will now produce a substantially great...
متن کاملNew insights to fibroblast growth factor 23 in kidney transplant.
Some abnormalities in mineral metabolism are evident even at very early stages of chronic kidney disease (CKD) and are important determinants of subsequent bone and cardiovascular disease.1,2 A decade ago, fibroblast growth factor 23 (FGF23) was recognized by a few as the protein responsible for several rare inherited and acquired syndromes of osteomalacia and rickets.3,4 Only recently have stu...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Nephrology
سال: 2020
ISSN: 1121-8428,1724-6059
DOI: 10.1007/s40620-020-00715-2